01—Abstract
Summary
Summary of the 8-K filed February 6, 2025. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported fourth quarter and fiscal 2024 results on February 6, 2025, as furnished under Item 2.02 in Exhibit 99.1.
Total revenues for the fourth quarter were $627.7 milliona, up from $515.2 million, and full-year total revenues were $2,355.3 million, up from $1,887.1 million. INGREZZA fourth-quarter net product sales were $615 million, growing 23%, and fiscal 2024 INGREZZA net product sales were $2.3 billion, growing 26%. CRENESSITY, approved by the FDA in December 2024, generated $2 million in net product sales from initial pharmacy orders.
GAAP net income for the fourth quarter was $103.1 millionb ($1.00 diluted EPS) versus $147.7 million ($1.44) a year earlier, while full-year GAAP net income was $341.3 million ($3.29 diluted EPS) versus $249.7 million ($2.47). Full-year 2024 GAAP results included $138.4 million of charges associated with convertible senior notes and $71.7 million of collaboration development milestone expense. The company guided 2025 INGREZZA net product sales to $2.5 to $2.6 billion, with GAAP R&D expense of $960 to $1,010 million and GAAP SG&A expense of $1,110 to $1,130 million.
Guidance includes initiation of Phase 3 programs for osavampator in major depressive disorder and NBI-568 in schizophrenia in the first half of 2025, along with $60 millionc of expected development milestone expense. Cash, cash equivalents and marketable securities totaled approximately $1.8 billion at December 31, 2024, and the company completed a $300 million accelerated share repurchase in early February 2025, retiring approximately 2.3 million shares in total.
Other developments included CMS notification that INGREZZA qualifies for the small biotech exemption under the Medicare Drug Price Negotiation Program, and an amended Takeda collaboration under which Neurocrine will hold exclusive rights to osavampator worldwide except Japan, where Takeda will hold exclusive rights. The company also initiated a Phase 1 study of NBI-921355 for epilepsy and reported KINECT-HD and tardive dyskinesia data for INGREZZA.
02—Key points
Key Highlights
- Fourth-quarter 2024 total revenues of $627.7 million, up from $515.2 million, with INGREZZA net sales of $615 million growing 23% year over year
- Full-year 2024 total revenues of $2,355.3 million and INGREZZA net product sales of $2.3 billion, growing 26%
- CRENESSITY, approved by the FDA in December 2024, recorded $2 million in net product sales reflecting initial pharmacy orders
- Fourth-quarter GAAP net income of $103.1 million ($1.00 diluted EPS) versus $147.7 million ($1.44) in the prior-year quarter; Non-GAAP net income of $173.4 million ($1.69 diluted EPS)
- 2025 guidance: INGREZZA net product sales of $2.5 to $2.6 billion; GAAP R&D of $960 to $1,010 million; GAAP SG&A of $1,110 to $1,130 million
- Cash, cash equivalents and marketable securities of approximately $1.8 billion at December 31, 2024; $300 million accelerated share repurchase completed in early February 2025
- Amended Takeda collaboration gives Neurocrine exclusive osavampator rights worldwide except Japan; Phase 3 programs for osavampator (MDD) and NBI-568 (schizophrenia) to begin in first half of 2025
03—Questions
Frequently Asked Questions
How did INGREZZA perform in fiscal 2024?
INGREZZA net product sales were $615 million in the fourth quarter, growing 23% compared with fourth quarter 2023, driven by strong underlying patient demand and improved gross-to-net dynamics. Full-year 2024 INGREZZA net product sales were $2.3 billion, growing 26%.
What is the early commercial performance of CRENESSITY?
CRENESSITY generated $2 million in net product sales in both the fourth quarter and fiscal 2024, reflecting initial pharmacy orders following FDA approval in December 2024 as an adjunctive treatment for classic congenital adrenal hyperplasia.
What drove the decline in GAAP net income?
Fourth-quarter 2024 GAAP net income fell to $103.1 million from $147.7 million. The filing cites higher operating expenses to support the expanding R&D portfolio, CRENESSITY pre-launch investments, and the INGREZZA sales force expansion, along with $66 million of stock-based compensation expense versus $38 million a year earlier. Full-year GAAP results also reflected $138.4 million of charges associated with convertible senior notes.
What are the company's 2025 financial expectations?
The company guided 2025 INGREZZA net product sales to $2.5 to $2.6 billion, GAAP R&D expense to $960 to $1,010 million, and GAAP SG&A expense to $1,110 to $1,130 million. Non-GAAP R&D guidance is $890 to $940 million and Non-GAAP SG&A guidance is $955 to $975 million.
What changed in the osavampator arrangement with Takeda?
Under the amended collaboration, Neurocrine will obtain exclusive rights to develop and commercialize osavampator in all territories worldwide except Japan, where Takeda will acquire exclusive rights. Each company is responsible for development costs in its region, and both are eligible to receive royalty payments.
04—Continue